Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 15 06 2020
accepted: 30 08 2020
pubmed: 26 9 2020
medline: 15 5 2021
entrez: 25 9 2020
Statut: ppublish

Résumé

While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care. HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis. Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001). The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.

Sections du résumé

BACKGROUND BACKGROUND
While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care.
METHODS METHODS
HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis.
RESULTS RESULTS
Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001).
CONCLUSIONS CONCLUSIONS
The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.

Identifiants

pubmed: 32975686
doi: 10.1245/s10434-020-09156-4
pii: 10.1245/s10434-020-09156-4
pmc: PMC8099037
mid: NIHMS1695930
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1929-1936

Subventions

Organisme : NCI NIH HHS
ID : T32 CA211034
Pays : United States
Organisme : NIH HHS
ID : T32CA211034
Pays : United States

Références

Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Gastroenterol Hepatol (N Y). 2019 Aug;15(8):423-430
pubmed: 31592079
J Viral Hepat. 2015 Sep;22(9):727-36
pubmed: 25581816
Dig Dis Sci. 2015 Jul;60(7):2183-9
pubmed: 25724166
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22
pubmed: 15042359
J Clin Gastroenterol. 2016 Mar;50(3):258-65
pubmed: 26352107
Front Oncol. 2018 Dec 03;8:579
pubmed: 30560091
J Natl Compr Canc Netw. 2015 May;13(5):543-9
pubmed: 25964640
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940
pubmed: 31413528
J Environ Health Sci. 2019;5(2):90-92
pubmed: 32104722
Hepatol Commun. 2018 Sep 24;2(10):1274-1283
pubmed: 30288480
Clin Gastroenterol Hepatol. 2018 Jan;16(1):106-114.e5
pubmed: 28756056
Health Care Financ Rev. 1995 Fall;17(1):1-14
pubmed: 10153465
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48
pubmed: 30670200
J Hepatocell Carcinoma. 2017 May 17;4:71-79
pubmed: 28553624
Top Antivir Med. 2013 Feb-Mar;21(1):15-9
pubmed: 23596274
Dig Dis Sci. 2019 Apr;64(4):910-917
pubmed: 30835028
Cancer. 2017 Apr 1;123(7):1219-1227
pubmed: 27859019
World J Gastroenterol. 2019 Apr 7;25(13):1550-1559
pubmed: 30983815
JAMA Oncol. 2017 Apr 1;3(4):456-463
pubmed: 27657493
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
Clin Gastroenterol Hepatol. 2019 Mar;17(4):766-773
pubmed: 30056183
Cancer. 2018 Sep 1;124(17):3551-3559
pubmed: 30113700

Auteurs

Joshua P Kronenfeld (JP)

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Emily L Ryon (EL)

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

David Goldberg (D)

Division of Digestive Health and Liver Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.

Rachel M Lee (RM)

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Adam Yopp (A)

Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX, USA.

Annie Wang (A)

Division of Surgical Oncology, Department of Surgery, NYU Langone Health, New York, NY, USA.

Ann Y Lee (AY)

Division of Surgical Oncology, Department of Surgery, NYU Langone Health, New York, NY, USA.

Sommer Luu (S)

Division of Surgical Oncology, Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Cary Hsu (C)

Division of Surgical Oncology, Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Eric Silberfein (E)

Division of Surgical Oncology, Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Maria C Russell (MC)

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Alan S Livingstone (AS)

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Nipun B Merchant (NB)

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Neha Goel (N)

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. neha.goel@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH